Talk:Immunocore
Add topic | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||
| ||||||||||||||||||
 | The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
Suggested Addition
[edit]Suggested addition to article: "In June 2013, Immunocore signed a deal with Genentech, worth between $10 and $30 million per programme, for the discovery and development of cancer treatments [1] http://www.fiercebiotech.com/press-releases/immunocore-and-genentech-enter-strategic-alliance-develop-immtacs-multiple" [2] http://www.independent.co.uk/news/science/exclusive-cancer--a-cure-just-got-closer-thanks-to-a-tiny-british-company--and-the-result-could-change-lives-of-millions-8707590.html Pool59 (talk) 12:48, 22 July 2013 (UTC)
Done I changed the source b/c there was very little info about Genentech in the Independent piece and a company press release is no the best source. NickCT (talk) 19:48, 23 July 2013 (UTC)
Immunocore’s novel bispecific biologics are based on precision-engineered, soluble T cell receptors, known as ImmTACs (Immune mobilising mTCR Against Cancer). [3] http://www.nature.com/nm/journal/v18/n6/full/nm.2764.html [4] http://www.landesbioscience.com/journals/oncoimmunology/article/22891/ Pool59 (talk) 14:35, 2 August 2013 (UTC)
- Done I rephrased significantly and added a little background on T-cell receptors. NickCT (talk) 19:27, 5 August 2013 (UTC)
Bold Changes
[edit]I am going to be bold and make some changes to the article which I believe will improve it. First of all, the history should come before the discussion of the background scientific information explaining what the company does. So I am just moving history to the top. After I do that, I will see what other improvements can be made.Feelingfancyfree (talk) 09:04, 29 April 2015 (UTC)
ImmTAV
[edit]Professor Lucy Dorrell and her team at the University of Oxford worked with Immunocore Ltd - a UK biotechnology company based in Oxfordshire - to investigate the potency of novel engineered immune-mobilising T cell receptors-based drugs ('ImmTAVs'), designed to clear HIV-infected cells.
I suggest that we consider including this revolutionary development in the article.[5][6][7] They are being used also for zika infection. MaynardClark (talk) 21:53, 22 July 2016 (UTC)
References
- ↑ Cite error: There are
<ref>tags on this page without content in them (see the help page). - ↑ Cite error: There are
<ref>tags on this page without content in them (see the help page). - ↑ Cite error: There are
<ref>tags on this page without content in them (see the help page). - ↑ Cite error: There are
<ref>tags on this page without content in them (see the help page). - ↑ PUBLIC RELEASE: 13-JUL-2016. Treatment targets HIV's last hiding place: Genetically engineered protein helps immune system see and kill cells containing dormant HIV, University of Oxford
- ↑ Immunocore’s ImmTAV shown to redirect the immune system to kill HIV-infected cells from patients treated with antiretroviral therapy, 8 June 2016
- ↑ New treatment may destroy HIV's last refuge. July 15, 2016 at 9:17 AM